Artificial Intelligence

Digital Biomanufacturing Market – Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

Published

11 months ago

May 25, 2023

<!– Name:DistributionId Value:8846618 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1199811 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:ccb78ce4-a7aa-43c2-80ac-8fdaaa3e84a0 –>

New York, May 25, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Digital Biomanufacturing Market – Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” – https://www.reportlinker.com/p06458562/?utm_source=GNW
Further, a surge in morbidity across the globe and enhanced interconnectivity of equipment and technologies has led to an increased burden on manufacturing operations. Other factors that influenced the market include higher competition, competitive pricing, inflation rate, technological advancements and evolving regulatory guidelines. These factors demanded a fundamental shift from conventional manufacturing operations, which subsequently led to the introduction of industry 4.0 technologies. Digital biomanufacturing has emerged as a promising alternative to mitigate a number of bioprocessing related concerns, as well as significantly promote process robustness and product quality.

Digital biomanufacturing, popularly known as bioprocessing 4.0, refers to the integration of physical equipment with digital software and platforms, such as process analytical technologies (PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twins, in order to streamline the overall biomanufacturing process. Implementation of these technologies in monitoring, analytics and computing capabilities is expected to revolutionize current biomanufacturing practices. Further, digital bioprocessing is believed to have transformed manufacturing principles in areas, such as process development, operational activities, logistics and supply chain management, when used in combination with advanced technologies, including artificial intelligence (AI), machine learning and internet of things (IoT).

SCOPE OF THE REPORT
The Digital Biomanufacturing Market: Distribution by Type of Technology (PAT, DAS, MES and Digital Twins), Deployment Options (Cloud-based and On-premises), Type(s) of Biologic(s) Manufactured (Antibodies, Cell Therapies and Gene Therapies, Proteins, Vaccines, and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and the likely future potential of the digital biomanufacturing market, over the next 12 years. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key inclusions of the report are briefly discussed below:

Growing Demand for Biologics
Breakthroughs in the biotechnology industry, over the last few decades, has provided a considerable boost to the overall development landscape of biopharmaceutical drugs. In 2022, a milestone was witnessed when the number of approvals received by biologics narrowly outpaced those reported by small molecules. Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies. This can be attributed to the fact that the demand for biologics has been constantly increasing and is supported by continuous innovation in this field. Specifically, advancements in niche segments is expected to culminate in accelerated growth of the biologics market.

Need for Digital Biomanufacturing
According to a recent report, the development of a new drug takes 10-15 years, with an overall investment of USD 1-2 billion. Despite the significant investment of resources, over 90% of the candidates fail at different stages of clinical trials, resulting in huge financial losses for biomanufacturers.

As a direct consequence of the consistently growing demand for biologics and the existing challenges, there is an increase in the requirement for solutions that help in establishment of a digitally enabled and connected end-to-end process, in order to optimize bioprocess operations. Research suggests that, at present, 20% of the organizations have already adopted digitalized approaches for biomanufacturing. Such approaches are expected to enable an uninterrupted and accessible supply of cost-effective drugs that are likely to be launched commercially, with reduced development timelines. In fact, several leading biopharma players have claimed to achieve 40% increase in quality, 15% reduction in cost, 80% decrease in process variability and 20% shorter operational timelines by leveraging digital biomanufacturing advances. , , ,

Key Advantages of Digital Biomanufacturing
Currently, batch-to-batch variation and product validation are considered as major bottlenecks faced by the biologic industry. Digital biomanufacturing harnesses various advancements, such as real-time monitoring, data analytics, automation, modelling, process optimization and other digital tools to transform the available information into actionable insights. This is expected to help in the creation of a uniform process, which is capable of decreasing the deviation in quality of each batch. Other key benefits of digital biomanufacturing include improved efficiency, higher product yield, better product quality, data integrity, reduced manual intervention and limited risk of contamination. It is worth noting that digitalization in biopharmaceutical manufacturing is becoming an essential requirement, given its potential to develop enhanced quality products, with high speed, agility and sustainability.

Current Market Landscape of Digital Biomanufacturing
The digital biomanufacturing providers landscape features a mix of large, mid-sized and small companies, which have the required expertise and offer various digital services for the production of biologics. At present, more than 140 digital technologies have been / are being developed by over 100 industry stakeholders to enable the manufacturing of biologics. Further, various types of technologies currently facilitate smart biomanufacturing; of these, 48% are based on the principles of PAT, followed by those using MES (28%), DAS (14%) and digital twins (10%).

Key Trends in the Digital Biomanufacturing Market
Many stakeholders are undertaking initiatives to forge alliance with other industry / non-industry players. It is worth highlighting that over 75 strategic partnerships related to digital biomanufacturing have been inked since 2018, indicating that software providers are actively upgrading their technology related capabilities and accommodating the current and anticipated demand for digital biomanufacturing. Given the inclination towards cutting-edge technologies, along with innovative approaches to tailor the bioprocessing, we believe that the digital biomanufacturing technologies market is likely to evolve at a rapid pace, over the coming years. ,

Market Size of the Digital Biomanufacturing Market
Driven by improved data analytics, better product yield, faster production timelines, access to real time operations and rising interest in paperless manufacturing amongst innovators, lucrative opportunities are expected to emerge for players offering bioprocessing 4.0 services. The digital biomanufacturing market is anticipated to grow at a CAGR of 11%, during the period 2023-2035. In terms of type of technology, the digital biomanufacturing market for digital twins is expected to grow at a relatively faster pace (19%), till 2035. Further, currently, the market for on-premise deployment options is expected to capture the majority share, however, this trend is likely to change in the foreseen future with the rising popularity of cloud-based technologies.

Example Players in the Digital Biomanufacturing Market
Examples of players engaged in this domain include (which have also been captured in this report) AspenTech, Bioreactors.net, Dassault Systèmes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Körber, Merck, Sartorius and Thermo Fisher Scientific.

The report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different regions. Amongst other elements, the report includes:
An executive summary of the insights captured during our research, offering a high-level view on the current state of the digital biomanufacturing market and its likely evolution in the mid-long term.
A general introduction to digital biomanufacturing, featuring a detailed discussion on various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing.
A detailed assessment of the overall market landscape of companies offering digital biomanufacturing technologies (PAT, DAS, MES and digital twins), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis).
A detailed competitiveness analysis of digital biomanufacturing technologies (PAT, DAS, MES and digital twins), based on supplier strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)) and type(s) of biologic(s) manufactured.
Elaborate profiles of key players (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing domain, which are actively providing software based on PAT, DAS, MES and digital twins. Each profile includes a brief overview of the company, along with information on capabilities of digital technologies offered by these firms, recent developments and an informed future outlook.
A benchmark analysis highlighting the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this domain, across key peer groups.
An analysis featuring information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.
A detailed analysis highlighting the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked.
A detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.

One of the key objectives of the report was to estimate the current opportunity and future growth potential of the digital biomanufacturing market. We have provided an informed estimate on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (PAT, DAS, MES and digital twins), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins, vaccines and others) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
Joel Sirois (President and Chief Executive Officer, BioIntelligence Technologies)
Klaus Mauch (Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology)
Ciaran O’Keeffe (Director, Business Development and Channel Sales, MasterControl) and Isura Sirisena (Quality and Manufacturing Digitization Specialist, MasterControl)
Yaron Halfon (Director of Sales, Trunovate)
Barbara Holtz (Business Consultant, Dassault Systèmes)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report was gathered via primary and secondary research. For all our projects, we conduct interviews / surveys with reputed domain experts (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
Question 1: What is the global market size of digital biomanufacturing?
Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.

Question 2: Which are the top players in the global digital biomanufacturing market?
Answer: Presently, more than 100 companies are engaged in digital biomanufacturing, worldwide. The top players engaged in this domain (which have also been captured in this report) include AspenTech, Bioreactors.net, Dassault Systèmes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Körber, Merck, Sartorius and Thermo Fisher Scientific.

Question 3: What are the factors driving the digital biomanufacturing market?
Answer: Increasing number of approved biologics, growing number of biologics-related clinical trials, rise in R&D activity and a shift in preference for cloud-based processes, over the traditional biomanufacturing operations, has bolstered the demand for digital biomanufacturing software.

Question 4: Which region has the highest market share in the global digital biomanufacturing market?
Answer: North America and Europe capture around 75% share in the current global digital biomanufacturing market, followed by Asia-Pacific.

Question 5: What are the leading market segments in digital biomanufacturing market?
Answer: Currently, in terms of type of technology, process analytical technology captures the largest share (close to 50%) in the global digital biomanufacturing market. However, digital twins are likely to witness higher annual growth rates in the upcoming years, owing to their rising popularity. Further, in terms of type of company, software providers hold the largest share in the digital biomanufacturing market as compared to CDMOs.

Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?
Answer: At present, the global biomanufacturing market is dominated by the players providing on-premises deployment options, while the market is anticipated to shift towards the use of cloud-based technologies in the near future.

Question 7: What are the partnership and collaboration trends in the digital biomanufacturing domain?
Answer: At present, service alliances, technology utilization agreements and acquisitions are the most prominent types of partnerships inked between various stakeholders engaged in the digital biomanufacturing domain.

Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?
Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years.

CHAPTER OUTLINES

Chapter 1 is a preface providing an introduction to the full report, Digital Biomanufacturing Market, 2023-2035.

Chapter 2 is an executive summary of the insights captured during our research, offering a high-level view on the current state of the digital biomanufacturing market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to digital biomanufacturing. It further includes a detailed discussion on the various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing.

Chapter 4 includes a detailed assessment of the overall market landscape of companies offering digital biomanufacturing technologies (PAT, DAS, MES, digital twins), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry).

Chapter 5 presents a detailed competitiveness analysis of digital biomanufacturing technologies (PAT, DAS, MES and digital twins) based on company strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)), and type(s) of biologic(s) manufactured.

Chapter 6 features elaborate profiles of key players (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing domain, which are actively providing software based on PAT, DAS, MES and digital twins. Each profile includes a brief overview of the company, along with information on the capabilities of digital technologies offered by these firms, recent developments and an informed future outlook.

Chapter 7 presents benchmark analysis of the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this domain, across key peer groups.

Chapter 8 features information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.

Chapter 9 highlights our opinion on the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked.

Chapter 10 presents a detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.

Chapter 11 presents a comprehensive market forecast analysis, highlighting the future potential of the market till 2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (PAT, DAS, MES and digital twins), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins vaccines, and others), and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).

Chapter 12 is a summary of the overall report. The chapter provides the key takeaways from the report, and presents facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the digital biomanufacturing market.

Chapter 13 is a collection of transcripts of interviews conducted with various stakeholders in the industry. We have presented details of interviews held Joel Sirois (President and Chief Executive Officer, BioIntelligence Technologies), Klaus Mauch (Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology), Ciaran O’Keeffe (Director, Business Development and Channel Sales, MasterControl), Isura Sirisena (Quality and Manufacturing Digitization Specialist, MasterControl), Yaron Halfon (Director of Sales, Trunovate) and Barbara Holtz (Business Consultant, Dassault Systèmes).

Chapter 14 is an appendix, which contains tabulated data and numbers for all the figures included in this report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.
Read the full report: https://www.reportlinker.com/p06458562/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Related Topics:AI Artificial Intelligence Machine learning

Up Next

Global Generic Drugs Market to Reach $671.5 Billion by 2030

Don't Miss

Clinical Decision Support System Market Primed to Reach USD 2.3 Billion by 2031 with 8.8% CAGR – TMR Study

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Building Energy Management Systems Market Projected to Reach $67.69 billion by 2030 – Exclusive Report by 360iResearch

Published

26 mins ago

April 25, 2024

CISION (PR Newswire)

PUNE, India, April 24, 2024 /PRNewswire/ — The report titled “Building Energy Management Systems Market by Component (Hardware, Services, Software), Type (Integrated Building Energy Management Systems, Standalone Building Energy Management Systems), Application, Deployment Mode, End-Use – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $34.52 billion in 2023 to reach $67.69 billion by 2030, at a CAGR of 10.09% over the forecast period.

“Revolutionizing Energy Efficiency Globally With The Evolution of Building Energy Management Systems (BEMS)”
In an era where energy conservation and efficiency have become paramount, building energy management systems (BEMS) are at the forefront of this transformation, offering solutions that monitor, control, and optimize energy usage within buildings. These advanced systems, leveraging real-time data analytics, automate energy control, enhance energy savings, reduce costs, and contribute to a greener planet. Primarily utilized in commercial spaces, residential areas, and industrial sectors, BEMS has a broad application scope, covering HVAC, lighting, and security systems. Factors driving the expansion of the BEMS market include escalating energy expenses, heightened awareness of environmental impacts, and the increasing incorporation of Internet of Things (IoT) and cloud-based technologies, coupled with supportive government initiatives promoting energy-efficient infrastructures. Although challenges such as high initial costs and technology integration barriers exist, the advent of AI and IoT technologies within BEMS heralds a future of predictive energy management and remote operational capabilities, with a growing emphasis on integrating renewable energy sources. Regions such as the United States, Canada, the European Union, and emerging economies such as China and India are witnessing significant growth in BEMS adoption, spurred by regulatory policies and a shift towards sustainable building practices. This global movement toward BEMS signals a step toward reducing carbon footprints and highlights the collective effort to embrace technology for a sustainable future.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/building-energy-management-systems
“Harnessing Energy Management for Sustainability and Efficiency”
Data centers are pivotal infrastructures in the digital transformation era, consuming up to 50 times more energy than typical commercial spaces. This energy demand positions data centers as key contributors to the U.S.’s overall electricity consumption. Recognizing this, implementing building energy management systems (BEMS) is crucial in mitigating the environmental impact and operational costs associated with data centers. BEMS optimizes cooling systems to prevent equipment overheating, thereby enhancing energy efficiency by leveraging real-time data. Such systems reduce the power usage effectiveness (PUE) ratio, highlighting a move toward more sustainable consumption patterns and ensuring data centers’ operational continuity. Integrating seamlessly with existing infrastructure, BEMS offers a comprehensive approach to energy management, enabling more innovative cooling, efficient power usage, and predictive maintenance. This transition highlights a commitment to environmental responsibility and fosters operational efficiency, setting a new standard for data center operations worldwide.
“Revolutionizing Building Efficiency With Advanced Energy Management Systems Optimized Usage”
In push toward sustainability, building energy management systems (BEMS) stands at the forefront of innovation, integrating sophisticated hardware such as sensors, actuators, controllers, and more to manage and reduce energy consumption in buildings meticulously. These systems work in concert to monitor environmental conditions and adjust heating, ventilation, and air conditioning (HVAC) settings in real time, leading to significant energy savings. BEMS provides valuable data that helps identify savings opportunities, while networking tools ensure seamless communication between devices by precisely tracking energy flow through meters. Servers process vast amounts of data, enabling detailed analysis and actionable insights to refine energy use further. Additionally, comprehensive services, including customized consultations and dedicated support, ensure that each BEMS is tailored to a building’s unique needs, providing efficient operation and extended system longevity. BEMS exemplifies the strategic shift toward more sustainable and operationally excellent building management through the collaborative synergy of hardware, software, and expert services.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/building-energy-management-systems
“Schneider Electric SE at the Forefront of Building Energy Management Systems Market with a Strong 13.97% Market Share”
The key players in the Building Energy Management Systems Market include Schneider Electric SE, Honeywell International Inc., Azbil Corporation, Emerson Electric Co., Johnson Controls International PLC, and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Building Energy Management Systems Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Building Energy Management Systems Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Building Energy Management Systems Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/building-energy-management-systems
“Dive into the Building Energy Management Systems Market Landscape: Explore 180 Pages of Insights, 566 Tables, and 26 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsBuilding Energy Management Systems Market, by ComponentBuilding Energy Management Systems Market, by TypeBuilding Energy Management Systems Market, by ApplicationBuilding Energy Management Systems Market, by Deployment ModeBuilding Energy Management Systems Market, by End-UseAmericas Building Energy Management Systems MarketAsia-Pacific Building Energy Management Systems MarketEurope, Middle East & Africa Building Energy Management Systems MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/building-energy-management-systems
Related Reports:
Home Energy Management System Market – Global Forecast 2024-2030Energy Management System Market – Global Forecast 2024-2030Intelligent Building Automation Technologies Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/building-energy-management-systems-market-projected-to-reach-67-69-billion-by-2030—exclusive-report-by-360iresearch-302124905.html

Artificial Intelligence

Terra Drone, Unifly, and Aloft Launch UTM Development for AAM Targeting Global Markets

Published

4 hours ago

April 24, 2024

CISION (PR Newswire)

terra-drone,-unifly,-and-aloft-launch-utm-development-for-aam-targeting-global-markets

TOKYO, April 25, 2024 /PRNewswire/ — Terra Drone Corporation, a leading drone and Advanced Air Mobility (AAM) technology provider headquartered in Japan, announced today the launch of joint development with its Group companies Unifly NV (“Unifly”) and Aloft Technologies Inc. (“Aloft”) focused on UAS Traffic Management (UTM) for AAMs targeting global markets. Terra Drone has been making strides in its pioneering UTM business via strategic investments in Unifly, a leading UTM technology provider based in Belgium, and Aloft, which has the top UTM market share in the U.S. This collaboration marks the world’s first-ever joint UTM development for AAMs by multiple companies with extensive track records in UTM implementation and operation.

The three companies pursue joint UTM development to capitalize on the rapid global progress in electric vertical take-off and landing aircrafts (eVTOLs), set to revolutionize transportation. Morgan Stanley forecasts the Urban Air Mobility (UAM) market to reach $1 trillion by 2040 and $9 trillion by 2050 (1), with eVTOLs gaining global recognition through test flights and prototype showcases.
The companies proudly announce initiatives to enhance their existing UTM platforms in anticipation of the surge in eVTOL aircraft and drone activities. The shared vision for the UTM platform is to enable safe and efficient flight operations for eVTOLs and drones in the foreseeable future.
Recognizing the evolving needs of the AAM industry, they are dedicated to extending their platform by incorporating crucial additional functions. These enhancements, designed with automation at their core, aim to streamline operational efficiencies and pave the way for the integration of their increasingly automated UTM technology into the design and operational framework of AAMs. Through these efforts, they aim to set new standards in UTM and to facilitate the seamless integration of eVTOLs and drones into the national airspace, bolstering the potential for the AAM industry.
Through this initiative, they aim to build a global UTM infrastructure that kickstarts the AAM industry worldwide, creating a cohesive ecosystem that supports AAM growth and addresses broader challenges of urban mobility, sustainability, and air traffic safety.
Notes to Editor:
Research by Morgan Stanley in a report titled “eVTOL/Urban Air Mobility TAM Update: A Slow Take-Off, But Sky’s the Limit” https://advisor.morganstanley.com/the-busot-group/documents/field/b/bu/busot-group/Electric%20Vehicles.pdf]
Photo – https://mma.prnewswire.com/media/2396553/Terra_Drone.jpgLogo – https://mma.prnewswire.com/media/2186129/Terra_Drone_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/terra-drone-unifly-and-aloft-launch-utm-development-for-aam-targeting-global-markets-302126451.html

Artificial Intelligence

IBM to Acquire HashiCorp, Inc. Creating a Comprehensive End-to-End Hybrid Cloud Platform

Published

6 hours ago

April 24, 2024

CISION (PR Newswire)

ibm-to-acquire-hashicorp,-inc.-creating-a-comprehensive-end-to-end-hybrid-cloud-platform

$6.4 billion acquisition adds suite of leading hybrid and multi-cloud lifecycle management products to help clients grappling with today’s AI-driven application growth and complexity
HashiCorp’s capabilities to drive significant synergies across multiple strategic growth areas for IBM, including Red Hat, watsonx, data security, IT automation and Consulting
As a part of IBM, HashiCorp is expected to accelerate innovation and enhance its go-to-market, growth and monetization initiatives
Transaction expected to be accretive to Adjusted EBITDA within the first full year, post close, and free cash flow in year two
ARMONK, N.Y. and SAN FRANCISCO, April 24, 2024 /PRNewswire/ — IBM (NYSE: IBM) and HashiCorp Inc. (NASDAQ: HCP), a leading multi-cloud infrastructure automation company, today announced they have entered into a definitive agreement under which IBM will acquire HashiCorp for $35 per share in cash, representing an enterprise value of $6.4 billion. HashiCorp’s suite of products provides enterprises with extensive Infrastructure Lifecycle Management and Security Lifecycle Management capabilities to enable organizations to automate their hybrid and multi-cloud environments. Today’s announcement is a continuation of IBM’s deep focus and investment in hybrid cloud and AI, the two most transformational technologies for clients today.

“Enterprise clients are wrestling with an unprecedented expansion in infrastructure and applications across public and private clouds, as well as on-prem environments. The global excitement surrounding generative AI has exacerbated these challenges and CIOs and developers are up against dramatic complexity in their tech strategies,” said Arvind Krishna, IBM chairman and chief executive officer. “HashiCorp has a proven track record of enabling clients to manage the complexity of today’s infrastructure and application sprawl. Combining IBM’s portfolio and expertise with HashiCorp’s capabilities and talent will create a comprehensive hybrid cloud platform designed for the AI era.”
The rise of cloud-native workloads and associated applications is driving a radical expansion in the number of cloud workloads enterprises are managing. In addition, generative AI deployment continues to grow alongside traditional workloads. As a result, developers are working with increasingly heterogeneous, dynamic, and complex infrastructure strategies. This represents a massive challenge for technology professionals.
HashiCorp’s capabilities enable enterprises to use automation to deliver lifecycle management for infrastructure and security, providing a system of record for the critical workflows needed for hybrid and multi-cloud environments. HashiCorp’s Terraform is the industry standard for infrastructure provisioning in these environments. HashiCorp’s offerings help clients take a cloud-agnostic, and highly interoperable approach to multi-cloud management, and complement IBM’s commitment to industry collaboration (including deep and expanding partnerships with hyperscale cloud service providers), developer communities, and open-source hybrid cloud and AI innovation.
“Our strategy at its core is about enabling companies to innovate in the cloud, while providing a consistent approach to managing cloud at scale. The need for effective management and automation is critical with the rise of multi-cloud and hybrid cloud, which is being accelerated by today’s AI revolution,” said Armon Dadgar, HashiCorp co-founder and chief technology officer. “I’m incredibly excited by today’s news and to be joining IBM to accelerate HashiCorp’s mission and expand access to our products to an even broader set of developers and enterprises.”
“Today is an exciting day for our dedicated teams across the world as well as the developer communities we serve,” said Dave McJannet, HashiCorp chief executive officer. “IBM’s leadership in hybrid cloud along with its rich history of innovation, make it the ideal home for HashiCorp as we enter the next phase of our growth journey. I’m proud of the work we’ve done as a standalone company, I am excited to be able to help our customers further, and I look forward to the future of HashiCorp as part of IBM.”
Transaction Rationale
Strong Strategic Fit – The acquisition of HashiCorp by IBM creates a comprehensive end-to-end hybrid cloud platform built for AI-driven complexity. The combination of each company’s portfolio and talent will deliver clients extensive application, infrastructure and security lifecycle management capabilitiesAccelerates growth in key focus areas – Upon close, HashiCorp is expected to drive significant synergies for IBM, including across multiple strategic growth areas like Red Hat, watsonx, data security, IT automation and Consulting. For example, the powerful combination of Red Hat’s Ansible Automation Platform’s configuration management and Terraform’s automation will simplify provisioning and configuration of applications across hybrid cloud environments. The two companies also anticipate an acceleration of HashiCorp’s growth initiatives by leveraging IBM’s world-class go-to-market strategy, scale, and reach, operating in more than 175 countries across the globeExpands Total Addressable Market (TAM) – The acquisition will create the opportunity to deliver more comprehensive hybrid and multi-cloud offerings to enterprise clients. HashiCorp’s offerings, combined with IBM and Red Hat, will give clients a platform to automate the deployment and orchestration of workloads across evolving infrastructure including hyperscale cloud service providers, private clouds and on-prem environments. This will enhance IBM’s ability to address the total cloud opportunity, which according to IDC had a TAM of $1.1 trillion in 2023, with a compound annual growth rate in the high teens through 2027.1Attractive Financial Opportunity – The transaction will accelerate IBM’s growth profile over time driven by go-to-market and product synergies. This growth combined with operating efficiencies, is expected to achieve substantial near-term margin expansion for the acquired business. It is anticipated that the transaction will be accretive to Adjusted EBITDA within the first full year, post close, and free cash flow in year two.HashiCorp boasts a roster of more than 4,400 clients, including Bloomberg, Comcast, Deutsche Bank, GitHub, J.P Morgan Chase, Starbucks and Vodafone. HashiCorp’s offerings have widescale adoption in the developer community and are used by 85% of the Fortune 500. Their community products across infrastructure and security were downloaded more than 500 million times in HashiCorp’s FY2024 and include:
Terraform – provides organizations with a single workflow to provision their cloud, private datacenter, and SaaS infrastructure and continuously manage infrastructure throughout its lifecycleVault – provides organizations with identity-based security to automatically authenticate and authorize access to secrets and other sensitive dataAdditional products – Boundary for secure remote access; Consul for service-based networking; Nomad for workload orchestration; Packer for building and managing images as code; and Waypoint internal developer platformTransaction Details
Under the terms of the agreement, IBM will acquire HashiCorp for $35 per share in cash, or $6.4 billion enterprise value, net of cash. HashiCorp will be acquired with available cash on hand.
The boards of directors of IBM and HashiCorp have both approved the transaction. The acquisition is subject to approval by HashiCorp shareholders, regulatory approvals and other customary closing conditions.
The Company’s largest shareholders and investors, who collectively hold approximately 43% of the voting power of HashiCorp’s outstanding common stock, entered into a voting agreement with IBM pursuant to which each has agreed to vote all of their common shares in favor of the transaction and against any alternative transactions.
The transaction is expected to close by the end of 2024.
____________________1 The total cloud opportunity is the sum of the cloud-directed spends across Hardware, IT services and SW for Private and Public cloud implementation, sourced from IDC’s Worldwide Black Book Live Edition, March 2024 (V1 2024)
Conference Call Details
IBM’s regular quarterly earnings conference call is scheduled to begin at 5:00 p.m. ET, today. The Webcast may be accessed here. Presentation charts will be available shortly before the Webcast.
About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.
About HashiCorp
HashiCorp is The Infrastructure Cloud™ company, helping organizations automate multi-cloud and hybrid environments with Infrastructure Lifecycle Management and Security Lifecycle Management. HashiCorp offers The Infrastructure Cloud on the HashiCorp Cloud Platform (HCP) for managed cloud services, as well as self-hosted enterprise offerings and community source-available products. The company is headquartered in San Francisco, California. For more information, visit HashiCorp.com.
Press Contacts:
IBM:Tim Davidson, [email protected]
HashiCorp:Matthew Sherman / Jed Repko / Haley Salas / Joycelyn BarnettJoele Frank, Wilkinson Brimmer Katcher212-355-4449

Additional Information and Where to Find It
HashiCorp, Inc. (“HashiCorp”), the members of HashiCorp’s board of directors and certain of HashiCorp’s executive officers are participants in the solicitation of proxies from stockholders in connection with the pending acquisition of HashiCorp (the “Transaction”). HashiCorp plans to file a proxy statement (the “Transaction Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies to approve the Transaction. David McJannet, Armon Dadgar, Susan St. Ledger, Todd Ford, David Henshall, Glenn Solomon and Sigal Zarmi, all of whom are members of HashiCorp’s board of directors, and Navam Welihinda, HashiCorp’s chief financial officer, are participants in HashiCorp’s solicitation. Information regarding such participants, including their direct or indirect interests, by security holdings or otherwise, will be included in the Transaction Proxy Statement and other relevant documents to be filed with the SEC in connection with the Transaction. Additional information about such participants is available under the captions “Board of Directors and Corporate Governance,” “Executive Officers” and “Security Ownership of Certain Beneficial Owners and Management” in HashiCorp’s definitive proxy statement in connection with its 2023 Annual Meeting of Stockholders (the “2023 Proxy Statement”), which was filed with the SEC on May 17, 2023 (and is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/1720671/000114036123025250/ny20008192x1_def14a.htm). To the extent that holdings of HashiCorp’s securities have changed since the amounts printed in the 2023 Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC (which are available at https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001720671&type=&dateb=&owner=only&count=40&search_text=). Information regarding HashiCorp’s transactions with related persons is set forth under the caption “Related Person Transactions” in the 2023 Proxy Statement. Certain illustrative information regarding the payments to that may be owed, and the circumstances in which they may be owed, to HashiCorp’s named executive officers in a change of control of HashiCorp is set forth under the caption “Executive Compensation—Potential Payments upon Termination or Change in Control” in the 2023 Proxy Statement. With respect to Ms. St. Ledger, certain of such illustrative information is contained in the Current Report on Form 8-K filed with the SEC on June 7, 2023 (and is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/1720671/000162828023021270/hcp-20230607.htm). Promptly after filing the definitive Transaction Proxy Statement with the SEC, HashiCorp will mail the definitive Transaction Proxy Statement and a WHITE proxy card to each stockholder entitled to vote at the special meeting to consider the Transaction. STOCKHOLDERS ARE URGED TO READ THE TRANSACTION PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT HASHICORP WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the preliminary and definitive versions of the Transaction Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by HashiCorp with the SEC in connection with the Transaction at the SEC’s website (http://www.sec.gov). Copies of HashiCorp’s definitive Transaction Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by HashiCorp with the SEC in connection with the Transaction will also be available, free of charge, at HashiCorp’s investor relations website (https://ir.hashicorp.com/), or by emailing HashiCorp’s investor relations department ([email protected]).
Forward-Looking Statements
Certain statements contained in this communication may be characterized as forward-looking under the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially.
Statements in this communication regarding IBM and HashiCorp that are forward-looking may include statements regarding: (i) the Transaction; (ii) the expected timing of the closing of the Transaction; (iii) considerations taken into account in approving and entering into the Transaction; (iv) the anticipated benefits to, or impact of, the Transaction on IBM’s and HashiCorp’s businesses; and (v) expectations for IBM and HashiCorp following the closing of the Transaction. There can be no assurance that the Transaction will be consummated.
Risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements, in addition to those identified above, include: (i) the possibility that the conditions to the closing of the Transaction are not satisfied, including the risk that required approvals from HashiCorp’s stockholders for the Transaction or required regulatory approvals to consummate the Transaction are not obtained, on a timely basis or at all; (ii) the occurrence of any event, change or other circumstance that could give rise to a right to terminate the Transaction, including in circumstances requiring HashiCorp to pay a termination fee; (iii) possible disruption related to the Transaction to IBM’s and HashiCorp’s current plans, operations and business relationships, including through the loss of customers and employees; (iv) the amount of the costs, fees, expenses and other charges incurred by IBM and HashiCorp related to the Transaction; (v) the risk that IBM’s or HashiCorp’s stock price may fluctuate during the pendency of the Transaction and may decline if the Transaction is not completed; (vi) the diversion of IBM and HashiCorp management’s time and attention from ongoing business operations and opportunities; (vii) the response of competitors and other market participants to the Transaction; (viii) potential litigation relating to the Transaction; (ix) uncertainty as to timing of completion of the Transaction and the ability of each party to consummate the Transaction; and (x) other risks and uncertainties detailed in the periodic reports that IBM and HashiCorp filed with the SEC, including IBM’s and HashiCorp’s respective Annual Reports on Form 10-K. All forward-looking statements in this communication are based on information available to IBM and HashiCorp as of the date of this communication, and, except as required by law, IBM and HashiCorp do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.
Logo – https://mma.prnewswire.com/media/2319830/IBM_LOGO_1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ibm-to-acquire-hashicorp-inc-creating-a-comprehensive-end-to-end-hybrid-cloud-platform-302126677.html